Who are Atomoxetine and OROS Methylphenidate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atomoxetine-and-oros-methylphenidate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atomoxetine and OROS Methylphenidate — Competitive Intelligence Brief

Atomoxetine and OROS Methylphenidate (Atomoxetine and OROS Methylphenidate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine reuptake inhibitor + stimulant combination. Area: Psychiatry / Neurology.

marketed Norepinephrine reuptake inhibitor + stimulant combination Norepinephrine transporter (NET); dopamine transporter (DAT) and norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Atomoxetine and OROS Methylphenidate (Atomoxetine and OROS Methylphenidate) — Massachusetts General Hospital. This is a combination of two norepinephrine-enhancing medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and OROS methylphenidate (an extended-release stimulant that increases dopamine and norepinephrine).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atomoxetine and OROS Methylphenidate TARGET	Atomoxetine and OROS Methylphenidate	Massachusetts General Hospital	marketed	Norepinephrine reuptake inhibitor + stimulant combination	Norepinephrine transporter (NET); dopamine transporter (DAT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine reuptake inhibitor + stimulant combination class)

Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atomoxetine and OROS Methylphenidate — Competitive Intelligence Brief. https://druglandscape.com/ci/atomoxetine-and-oros-methylphenidate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab